We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 23, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Allergan (NYSE:AGN – Free Report), Ecolab (NYSE:ECL – Free Report), Exelon (NYSE:EXC – Free Report), GlaxoSmithKline (NYSE:GSK – Free Report) and Rockwell Collins (NYSE:COL – Free Report).
Top Analyst Reports for Allergan, Ecolab, Exelon & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Allergan (NYSE: – Free Report), Ecolab (NYSE:(ECL - Free Report) – Free Report) and Exelon (NYSE:(EXC - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Allergan’s shares have gained +7.1% year to date, outperforming the Zacks Generic Drugs industry, which has declined -19.3% over the same period. Allergan beat estimates for both earnings and sales in the second quarter. Meanwhile, the company raised its 2017 sales and earnings outlook.
The Zacks analyst likes key products like Botox and Linzess as well as new products such as Viberzi and Vraylar which are supporting sales growth. Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions.
With the closing of the Teva deal, Allergan can now focus on the branded segment. It also boasts a strong branded pipeline with meaningful data read-outs expected in the near term. However, Allergan is facing generic competition for legacy brands like Namenda XR and Asacol HD, which concerns us. Also, competition for key growth drivers like Restasis is a concern.
Shares of Ecolab have gained +11.9% year-to-date, outperforming the Zacks Specialty Chemicals industry which has increased +8.5% over the same period. Ecolab’s second-quarter earnings and revenues surpassed expectations. The Zacks analyst likes Ecolab’s robust product portfolio and expanding customer base, which will likely drive Ecolab organic sales over the long haul. In fact, the realization of targeted synergies associated with acquisitions should also pave way for margin expansion.
The company expects its water, food and beverage, and paper businesses to benefit in the near term. On the flipside, Ecolab operates in highly competitive markets, which might dent its prospects over the long haul. Volatility in foreign currency exchange rates will remain a significant headwind for the company. Ecolab also faces pricing pressure in the Energy segment which is likely to hurt profits.
Exelon shares have gained +14% over the last one year, outperforming the Zacks Electric Power Industry which has gained +8.9% over the same period. The company’s second-quarter earnings and total revenue exceeded expectations due to higher utility earnings attributable to regulatory rate increases.
The Zacks analyst thinks Exelon is well positioned to gain from rate revisions and strong operational performance across its business. Further, the company is benefiting from the Pepco Holdings acquisition. However, Exelon is subject to the impact of commodity price volatility, price fluctuation in the wholesale markets and unfavorable weather conditions. Stringent government regulation is also a cause for concern.
Other noteworthy reports we are featuring today include GlaxoSmithKline (NYSE:(GSK - Free Report) – Free Report) and Rockwell Collins (NYSE: – Free Report).
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins
For Immediate Release
Chicago, IL – August 23, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Allergan (NYSE:AGN – Free Report), Ecolab (NYSE:ECL – Free Report), Exelon (NYSE:EXC – Free Report), GlaxoSmithKline (NYSE:GSK – Free Report) and Rockwell Collins (NYSE:COL – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Allergan, Ecolab, Exelon & More
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Allergan (NYSE: – Free Report), Ecolab (NYSE:(ECL - Free Report) – Free Report) and Exelon (NYSE:(EXC - Free Report) – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Allergan’s shares have gained +7.1% year to date, outperforming the Zacks Generic Drugs industry, which has declined -19.3% over the same period. Allergan beat estimates for both earnings and sales in the second quarter. Meanwhile, the company raised its 2017 sales and earnings outlook.
The Zacks analyst likes key products like Botox and Linzess as well as new products such as Viberzi and Vraylar which are supporting sales growth. Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions.
With the closing of the Teva deal, Allergan can now focus on the branded segment. It also boasts a strong branded pipeline with meaningful data read-outs expected in the near term. However, Allergan is facing generic competition for legacy brands like Namenda XR and Asacol HD, which concerns us. Also, competition for key growth drivers like Restasis is a concern.
(You canread the full research report on Allergan here >>>).
Shares of Ecolab have gained +11.9% year-to-date, outperforming the Zacks Specialty Chemicals industry which has increased +8.5% over the same period. Ecolab’s second-quarter earnings and revenues surpassed expectations. The Zacks analyst likes Ecolab’s robust product portfolio and expanding customer base, which will likely drive Ecolab organic sales over the long haul. In fact, the realization of targeted synergies associated with acquisitions should also pave way for margin expansion.
The company expects its water, food and beverage, and paper businesses to benefit in the near term. On the flipside, Ecolab operates in highly competitive markets, which might dent its prospects over the long haul. Volatility in foreign currency exchange rates will remain a significant headwind for the company. Ecolab also faces pricing pressure in the Energy segment which is likely to hurt profits.
(You can read the full research report on Ecolab here >>>).
Exelon shares have gained +14% over the last one year, outperforming the Zacks Electric Power Industry which has gained +8.9% over the same period. The company’s second-quarter earnings and total revenue exceeded expectations due to higher utility earnings attributable to regulatory rate increases.
The Zacks analyst thinks Exelon is well positioned to gain from rate revisions and strong operational performance across its business. Further, the company is benefiting from the Pepco Holdings acquisition. However, Exelon is subject to the impact of commodity price volatility, price fluctuation in the wholesale markets and unfavorable weather conditions. Stringent government regulation is also a cause for concern.
(You can read the full research report on Exelon here >>>).
Other noteworthy reports we are featuring today include GlaxoSmithKline (NYSE:(GSK - Free Report) – Free Report) and Rockwell Collins (NYSE: – Free Report).
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on AGN - FREE
Get the full Report on ECL - FREE
Get the full Report on EXC - FREE
Get the full Report on GSK - FREE
Get the full Report on COL - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.